ZURICH
Dec 12 (Reuters) – Roche (ROG.S) said on Monday the head of its pharmaceuticals unit had decided to leave after 16 years at the Swiss drugmaker, announcing a broader restructuring and early next year. Planned CEO change.
![Roche](https://cloudfront-us-east-2.images.arcpublishing.com/reuters/LXTTXLJFEFML3HBPFRRZPBZL5A.jpg)
Bill Anderson
The former head of Roche’s Genentech unit, will step down at the end of the year « to pursue opportunities outside Roche, » and a successor will be appointed in March 2023, Roche said in a statement.
Anderson’s departure from Roche’s biggest business means more fundamental leadership from Roche’s diagnostics chief executive Thomas Schinecker, who will be promoted to Group CEO in March.
He succeeds Roche Chief Executive Severin Schwan
Who led a successful year-long campaign to move away from Roche’s traditional focus on cancer.
But after family-controlled Roche suffered a series of development setbacks this year
Schinecker has the onus to revive the development pipeline: a high-profile Alzheimer’s drug trial stalled last month, a new lung cancer immunotherapy The drug candidate ran into trouble in May.
Shares of the Swiss company are down about 20% so far this year
Underperforming the STOXX Europe 600 Health Care (.SXDP) index’s 5% decline.
Anderson will be temporarily replaced by Schinecker
The company added.
Schinecker succeeds Severin Schwan
Who became chairman of the board after 14 years as Roche CEO.
« During Roche’s 16-year career
Bill Anderson has demonstrated outstanding leadership qualities. He has been instrumental in shaping Roche’s transformation and I wish him the best for the future, » Schwan said in a statement.
Anderson joined Genentech
California, in 2006 as Senior Vice President of the Immunology and Ophthalmology Business Units and later led the Bio-Oncology Business Unit.
Since 2019
He has been CEO of Roche’s pharmaceutical business.
In a proposal for next year’s annual general meeting
Roche also reiterated its intention to nominate Schwan as the next chairman.
Roche announced on Monday that
As announced in July 2022, Christoph Franz has decided not to run for president.
Nestlé SA (NESN.S ) Chief Executive Mark Schneider and Yale University immunobiology professor Akiko Iwasaki will run for new board members at next year’s annual meeting.
💡 Resources and references
« reuters.com », via: Roche boss Pharma leaves company..